SCHEDULE: Adage Capital Amends Aligos Therapeutics Stake

Adage Capital Management and its principals have filed an amended Schedule 13G, disclosing a 3.90% beneficial ownership in Aligos Therapeutics, Inc.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 210,000 shares of Aligos Therapeutics, Inc. Voting Common Stock.
• This ownership represents 3.90% of the company's outstanding Voting Common Stock.
• The reported shares include 70,000 shares issuable upon the exercise of warrants.
• The percentage is calculated based on 5,314,801 shares of Voting Common Stock outstanding as of May 1, 2025, as reported in Aligos Therapeutics' Form 10-Q for the quarter ended March 31, 2025.
• The filing is an Amendment No. 2 to a Schedule 13G, filed under Rule 13d-1(c).

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of beneficial ownership. While it doesn't contain operational news, the continued institutional investment by Adage Capital Management can be viewed as a neutral to slightly positive signal, indicating ongoing interest in Aligos Therapeutics.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of institutional ownership in a biotechnology company. It reflects an investment firm's position rather than operational or strategic updates from the company itself. Such filings are common in the highly capitalized and research-intensive biotechnology sector, where institutional investors frequently take positions.

Stakeholder Impact

• Shareholders: The filing confirms continued institutional investment in Aligos Therapeutics, which may be viewed positively as a sign of confidence from a notable investment firm.

Key Dates

Keywords

Aligos Therapeutics, Adage Capital Management, Beneficial Ownership, Schedule 13G, Institutional Investment, Voting Common Stock, Warrants, Biotechnology, Healthcare